

# Paolo Gisondi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3246719/publications.pdf>

Version: 2024-02-01

260  
papers

11,436  
citations

31976

53  
h-index

37204

96  
g-index

265  
all docs

265  
docs citations

265  
times ranked

8763  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 68-73.	0.9	53
2	Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis. <i>Dermatology</i> , 2022, 238, 276-282.	2.1	1
3	Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 80-85.	1.3	5
4	Predictors of subsequent primary melanoma: a case-control study. <i>Archives of Dermatological Research</i> , 2022, 314, 881-885.	1.9	1
5	Early predictors of psoriatic arthritis: a delphi based consensus from Italian dermatology centers. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	4
6	Skin adverse reactions to Sars-CoV-2 vaccination: a relevant responsibility issue for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 165-166.	2.4	1
7	Biological agents targeting interleukin-13 for atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 651-659.	3.1	8
8	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.5	11
9	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1277-1288.	3.3	26
10	Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare. <i>JAMA Dermatology</i> , 2022, 158, 375.	4.1	35
11	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	4.1	12
12	Corymbose Syphilis. <i>Sexually Transmitted Diseases</i> , 2022, 49, e85-e86.	1.7	0
13	Prevalence of most common skin diseases in Europe: a population-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1088-1096.	2.4	52
14	The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	0
15	Dermoscopic features of nevoid melanoma: a retrospective study with systematic literature review. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	0
16	Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	0
17	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, 1-78.	0.2	25
18	Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1579-1584.	3.1	6

#	ARTICLE	IF	CITATIONS
19	Is risankizumab as needed administration a good option for patients with plaque psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
20	Paradoxical Effect on Epidermal Barrier of Anti-TNF-alpha Treatment for Psoriasis.. Journal of Clinical and Aesthetic Dermatology, 2022, 15, 36-38.	0.1	0
21	Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines, 2022, 10, 646.	4.4	5
22	Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis. Dermatology and Therapy, 2022, 12, 1303-1311.	3.0	7
23	Scurvy as Presenting Sign of Anorexia Nervosa. Journal of Cutaneous Medicine and Surgery, 2022, 26, 645-645.	1.2	1
24	Association between short-term exposure to environmental air pollution and psoriasis flare. Bone Reports, 2022, 16, 101441.	0.4	0
25	Monkeypox virus infection: what dermatologist needs to know?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	10
26	Dupilumab for recalcitrant Kimura disease. Dermatologic Therapy, 2022, 35, .	1.7	8
27	Update on the Management of Pediatric Psoriasis: An Italian Consensus. Dermatology and Therapy, 2022, 12, 1753-1775.	3.0	11
28	Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. Journal of the American Academy of Dermatology, 2021, 85, 671-680.	1.2	27
29	Evidence for a "window of opportunity"™ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study*. British Journal of Dermatology, 2021, 184, 133-140.	1.5	88
30	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry—based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	2.9	136
31	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 2021, 21, 271-277.	3.1	40
32	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: ANorthern Italy experience. Journal of Allergy and Clinical Immunology, 2021, 147, 558-560.e1.	2.9	44
33	Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 693-700.	2.4	26
34	Place of apremilast in the real-life treatment of patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 13-13.	2.4	3
35	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	1.3	5
36	Increased red blood cell distribution width in patients with plaque psoriasis. Journal of Medical Biochemistry, 2021, 40, 199-201.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. <i>Dermatology</i> , 2021, 237, 1-5.	2.1	9
38	Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00422.	1.3	12
39	IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. <i>Dermatologic Therapy</i> , 2021, 34, e14889.	1.7	14
40	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 281-317.	2.4	84
41	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	2.4	6
42	Insights into SARS-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e361-e362.	2.4	9
43	Pruritus as a Distinctive Feature of Type 2 Inflammation. <i>Vaccines</i> , 2021, 9, 303.	4.4	66
44	Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e355-e357.	2.4	2
45	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
46	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.5	26
47	Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. <i>Dermatologic Therapy</i> , 2021, 34, e14949.	1.7	4
48	Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. <i>Dermatology and Therapy</i> , 2021, 11, 695-705.	3.0	17
49	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. <i>BioDrugs</i> , 2021, 35, 469-471.	4.6	7
50	The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1356-1363.	1.2	61
51	Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04153.	0.5	5
52	Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 247-253.	3.2	22
53	Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. <i>Dermatology and Therapy</i> , 2021, 11, 1333-1343.	3.0	17
54	Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature. <i>Case Reports in Dermatology</i> , 2021, 13, 282-288.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Considerations in association studies in dermatoeidemiology. British Journal of Dermatology, 2021, 185, 1-2.	1.5	0
56	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e709-e711.	2.4	2
57	Impact of the COVID-19 pandemic on melanoma diagnosis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e714-e715.	2.4	20
58	Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. Journal of Investigative Dermatology, 2021, , .	0.7	9
59	Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. Journal of the American Academy of Dermatology, 2021, , .	1.2	8
60	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	2.4	18
61	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. Journal of the American Academy of Dermatology, 2021, 85, 572-581.	1.2	36
62	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy, 2021, 11, 235-252.	3.0	34
63	Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Italian Journal of Dermatology and Venereology, 2021, 156, 455-459.	0.2	2
64	Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. Journal of Personalized Medicine, 2021, 11, 1069.	2.5	4
65	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	5.9	86
66	Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. Journal of Clinical Medicine, 2021, 10, 5344.	2.4	58
67	Ki67/MART1 and p63/SOX10 dual immunohistochemistry allows a correct interpretation of the melanocytic component in the diagnosis of pigmented pilomatricoma. Indian Journal of Dermatology, 2021, 66, 525.	0.3	0
68	Clinical profile and co-infections of urethritis in males. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	1
69	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clinical and Experimental Rheumatology, 2021, 39, 1099-1107.	0.8	2
70	Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
71	Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110669.	1.2	1
72	In vitro cell culture of amniotic fluid keratinocytes on amniotic membrane: the ideal tissue for repairing skin ulcers. European Review for Medical and Pharmacological Sciences, 2021, 25, 49-55.	0.7	0

#	ARTICLE	IF	CITATIONS
73	Visual Vignette. Endocrine Practice, 2020, 26, 253.	2.1	1
74	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
75	Does systemic treatment of psoriasis reduce the risk of comorbidities?. British Journal of Dermatology, 2020, 182, 823-824.	1.5	4
76	Psoriasin (S100A7) is increased in the serum of patients with moderate to severe psoriasis. British Journal of Dermatology, 2020, 182, 1502-1503.	1.5	11
77	Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. Journal of Clinical Medicine, 2020, 9, 3594.	2.4	13
78	Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): a systematic review. JDDG - Journal of the German Society of Dermatology, 2020, 18, 826-833.	0.8	8
79	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e770-e772.	2.4	31
80	Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatologic Therapy, 2020, 33, e14281.	1.7	12
81	Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. American Journal of Clinical Dermatology, 2020, 21, 749-751.	6.7	27
82	Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. Vaccines, 2020, 8, 769.	4.4	29
83	The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines, 2020, 8, 728.	4.4	27
84	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	2.4	6
85	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. Dermatology, 2020, 236, 329-335.	2.1	9
86	Brodalumab in the treatment of chronic plaque psoriasis. Expert Opinion on Biological Therapy, 2020, 20, 1175-1186.	3.1	8
87	Switching from one infliximab biosimilar (CTP13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. British Journal of Dermatology, 2020, 183, 397-398.	1.5	17
88	Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Frontiers in Pharmacology, 2020, 11, 117.	3.5	80
89	Consensus on the place in therapy of TNF inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472.	2.4	6
90	Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. Journal of Dermatology, 2020, 47, 578-582.	1.2	34

#	ARTICLE	IF	CITATIONS
91	Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. <i>Dermatologic Therapy</i> , 2020, 33, e13979.	1.7	15
92	Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2499-2504.	2.4	96
93	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1695-1706.	2.4	57
94	The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. <i>British Journal of Dermatology</i> , 2020, 183, 373-374.	1.5	104
95	Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. <i>Vaccine</i> , 2020, 38, 3808-3809.	3.8	1
96	Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 285-287.	1.2	49
97	A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 481-491.	3.1	6
98	Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 271-285.	2.3	20
99	Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1196-1201.	2.4	85
100	TNF- $\alpha$ inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	3.0	18
101	Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2168-2169.	2.4	4
102	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	2.4	149
103	Hidradenitis suppurativa and adalimumab in the COVID-19 era. <i>European Journal of Dermatology</i> , 2020, 30, 748-749.	0.6	9
104	SAT0412...ACCURACY OF AN INSTRUMENT FOR SCREENING PSORIATIC ARTHRITIS AMONG PSORIATIC PATIENTS: RESULTS FROM THE MULTICENTRE ITALIAN STUDY HERACLES (SCREENING STRATEGIES FOR) <i>Journal of the Rheumatic Diseases</i> , 2020, 79, 1158.2-1159.	0.9	0
105	Recognizing the differential impact of site of involvement on quality of life in dermatology. <i>British Journal of Dermatology</i> , 2019, 181, 229-230.	1.5	1
106	A systematic review of treatments for pityriasis lichenoides. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2039-2049.	2.4	28
107	A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 392-399.	0.8	4
108	Adalimumab in severe plaque psoriasis of childhood: A multicenter, retrospective real-life study up to 52-weeks observation. <i>Dermatologic Therapy</i> , 2019, 32, e13091.	1.7	21

#	ARTICLE	IF	CITATIONS
109	Is the routine screening for hyperhomocysteinaemia recommended in patients with chronic plaque psoriasis?. <i>British Journal of Dermatology</i> , 2019, 180, 262-263.	1.5	0
110	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 90-99.	3.5	34
111	Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. <i>British Journal of Dermatology</i> , 2019, 181, 1319-1320.	1.5	8
112	Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1512-1520.	1.9	9
113	Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 182, 175-179.	1.5	3
114	Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor- $\alpha$ to interleukin-17A inhibitor. <i>British Journal of Dermatology</i> , 2019, 181, 624-626.	1.5	3
115	The pharmacological management of patients with comorbid psoriasis and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 863-872.	1.8	23
116	Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e246-e247.	2.4	3
117	Glomerular filtration rate in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e244-e246.	2.4	4
118	Etanercept biosimilar <sc>SB</sc> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.5	17
119	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.5	30
120	The multifaceted association between psoriasis and obesity. <i>British Journal of Dermatology</i> , 2019, 180, 24-24.	1.5	2
121	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	1.2	362
122	Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. <i>Clinical and Experimental Immunology</i> , 2019, 199, 88-96.	2.6	14
123	Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 133-136.	0.8	20
124	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	2.9	16
125	Image Gallery: Pyoderma gangrenosum of the penis. <i>British Journal of Dermatology</i> , 2018, 178, e62.	1.5	0
126	Kyrle's disease effectively treated with oral isotretinoin. <i>Journal of Dermatological Treatment</i> , 2018, 29, 630-632.	2.2	7



#	ARTICLE	IF	CITATIONS
127	Psoriasis and the metabolic syndrome. <i>Clinics in Dermatology</i> , 2018, 36, 21-28.	1.6	211
128	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	2.4	15
129	Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. <i>Journal of Dermatological Treatment</i> , 2018, 29, 217-219.	2.2	30
130	The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. <i>Frontiers in Immunology</i> , 2018, 9, 1549.	4.8	279
131	The multidimensional burden of psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 13-14.	1.5	4
132	Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. <i>Medical Ultrasonography</i> , 2018, 20, 177.	0.8	23
133	How to improve adherence to treatment in patients with mild-to-moderate psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 692-697.	0.8	7
134	Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. <i>Journal of Dermatological Treatment</i> , 2017, 28, 129-135.	2.2	5
135	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1853-1859.	2.4	27
136	Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 863-869.	2.4	31
137	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 774-790.	2.4	140
138	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2017, 177, e325-e326.	1.5	19
139	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1591-1597.	0.9	52
140	Primary Cutaneous CD4 <sup>+</sup> Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 502-506.	1.2	14
141	Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2119-2123.	2.4	16
142	Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. <i>Dermatologic Therapy</i> , 2017, 30, e12503.	1.7	10
143	Could maternal stress increase the risk of developing psoriasis in the offspring?. <i>British Journal of Dermatology</i> , 2017, 176, 569-570.	1.5	0
144	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , 2017, 177, 197-205.	1.5	36

#	ARTICLE	IF	CITATIONS
145	High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema. <i>British Journal of Dermatology</i> , 2017, 177, 606-607.	1.5	5
146	European S3â€“Guideline on the systemic treatment of psoriasis vulgaris â€“ Update Apremilast and Secukinumab â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	2.4	116
147	Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin. <i>Journal of Dermatology</i> , 2017, 44, e332-e333.	1.2	0
148	Patientsâ€™ perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. <i>Journal of Dermatological Treatment</i> , 2017, 28, 390-393.	2.2	7
149	Treatment Approaches to Moderate to Severe Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2427.	4.1	96
150	Advanced Glycation End Products in the Pathogenesis of Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2471.	4.1	43
151	Effects of secukinumab on serum adipocytokines: preliminary data. <i>Reumatismo</i> , 2017, 69, 105.	0.9	9
152	Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 327-332.	0.2	7
153	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 251-252.	1.3	21
154	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1763.	4.3	26
155	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 217.	4.1	73
156	Heat urticaria: a revision of published cases with an update on classification and management. <i>British Journal of Dermatology</i> , 2016, 175, 473-478.	1.5	32
157	Nonâ€“alcoholic fatty liver disease fibrosis score in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 282-287.	2.4	50
158	Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 305-311.	3.4	12
159	Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis. <i>Pediatric Dermatology</i> , 2016, 33, 530-535.	0.9	34
160	Considerations for Systemic Treatment of Psoriasis in Obese Patients. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 609-615.	6.7	40
161	Glomerular filtration rate in patients with psoriasis treated with etanercept. <i>Journal of International Medical Research</i> , 2016, 44, 106-108.	1.0	8
162	Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 395-398.	2.2	35

#	ARTICLE	IF	CITATIONS
163	Adult atopic dermatitis: a review. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 403-11.	0.8	34
164	AB0821â€¦Baseline Characteristics of Patients with Moderate to Severe Psoriatic Arthritis: Post-Hoc Analysis of Responders vs Non-Responders to Etanercept. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1174-1174.	0.9	1
165	Therapeutic insights from the British Association of Dermatologists Biologic Interventions Register. <i>British Journal of Dermatology</i> , 2015, 173, 329-330.	1.5	0
166	Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. <i>British Journal of Dermatology</i> , 2015, 172, 1613-1620.	1.5	36
167	Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities. <i>Frontiers in Medicine</i> , 2015, 2, 1.	2.6	68
168	Dermatoepidemiology; what's up people?. <i>British Journal of Dermatology</i> , 2015, 173, 881-883.	1.5	1
169	European S3â€¦Guidelines on the systemic treatment of psoriasis vulgaris â€œ Update 2015 â€œ Short version â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	2.4	353
170	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV , multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1156-1163.	2.4	20
171	Skin moisturization for xerosis related to targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e33.	1.2	0
172	Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis. <i>Journal of Dermatological Science</i> , 2015, 78, 149-151.	1.9	21
173	Concept of Remission in Chronic Plaque Psoriasis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 57-60.	2.2	15
174	Annular Lichenoid Dermatitis of Youth: Report of Six New Cases with Review of the Literature. <i>Dermatology</i> , 2015, 231, 195-200.	2.1	25
175	<scp>PSOCUBE</scp>, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidenceâ€¦based algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1310-1317.	2.4	8
176	Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. <i>Acta Dermato-Venereologica</i> , 2014, 96, 96-101.	1.3	4
177	Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque-Type Psoriasis. <i>Drug Development Research</i> , 2014, 75, S31-S34.	2.9	12
178	Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. <i>British Journal of Dermatology</i> , 2014, 171, 884-890.	1.5	25
179	Hyperuricemia in Patients with Chronic Plaque Psoriasis. <i>Drug Development Research</i> , 2014, 75, S70-2.	2.9	10
180	Hyperuricemia in patients with chronic plaqueâ€¦psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 127-130.	1.2	45

#	ARTICLE	IF	CITATIONS
181	Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy. <i>Dermatology and Therapy</i> , 2014, 4, 1-9.	3.0	30
182	Skin rash and arthritis a simplified appraisal of less common associations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 679-688.	2.4	10
183	Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment. <i>Drug Development Research</i> , 2014, 75, S24-S26.	2.9	19
184	Seminars in Research 2013. <i>Drug Development Research</i> , 2014, 75, S1-S2.	2.9	0
185	Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis. <i>Dermatology</i> , 2014, 228, 78-85.	2.1	51
186	Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. <i>European Review for Medical and Pharmacological Sciences</i> , 2014, 18, 3435-52.	0.7	3
187	Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e30-41.	2.4	75
188	Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. <i>Immunologic Research</i> , 2013, 56, 382-389.	2.9	46
189	Survival rate of antitumour necrosis factor- $\hat{\pm}$ treatments for psoriasis in routine dermatological practice: a multicentre observational study. <i>British Journal of Dermatology</i> , 2013, 169, 666-672.	1.5	138
190	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2013, 24, 305-311.	2.2	28
191	Immunogenicity of anti-TNF $\hat{\pm}$ therapy in psoriasis: a clinical issue?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1673-1682.	3.1	56
192	The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 992-995.	0.9	73
193	Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. <i>British Journal of Dermatology</i> , 2013, 168, 749-755.	1.5	65
194	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. <i>British Journal of Dermatology</i> , 2013, 168, 1124-1127.	1.5	67
195	Impact of TNF- $\hat{\pm}$ antagonists on the quality of life in selected skin diseases. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2013, 148, 243-8.	0.8	9
196	Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2013, 148, 1-10.	0.8	19
197	The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. <i>Rheumatology</i> , 2012, 51, 2058-2063.	1.9	116
198	Weight Reduction Alone May Not Be Sufficient to Maintain Disease Remission in Obese Patients with Psoriasis: A Randomized, Investigator-Blinded Study. <i>Dermatology</i> , 2012, 224, 31-37.	2.1	29

#	ARTICLE	IF	CITATIONS
199	Ultrasonography reveals nail thickening in patients with chronic plaque psoriasis. Archives of Dermatological Research, 2012, 304, 727-732.	1.9	51
200	Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Annals of the Rheumatic Diseases, 2012, 71, 553-556.	0.9	136
201	Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. British Journal of Dermatology, 2012, 166, 775-783.	1.5	99
202	Psodisk, a new visual method for assessing the burden of psoriasis on patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1163-1166.	2.4	26
203	Vitamin D status in patients with chronic plaque psoriasis. British Journal of Dermatology, 2012, 166, 505-510.	1.5	120
204	Attitude to treatment of patients with psoriasis attending spa center. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 483-9.	0.8	6
205	Comparison of patients' and providers' severity evaluation of oral mucosal conditions. Journal of the American Academy of Dermatology, 2011, 65, 69-76.	1.2	22
206	Incidence of respiratory and allergic symptoms in Italian and immigrant children. Respiratory Medicine, 2011, 105, 204-210.	2.9	26
207	Phenotypes of atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2011, 9, 12-20.	0.8	52
208	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 2011, 303, 1-10.	1.9	690
209	Preliminary Evidence That Subclinical Enthesopathy May Predict Psoriatic Arthritis in Patients with Psoriasis. Journal of Rheumatology, 2011, 38, 2691-2692.	2.0	86
210	Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. Journal of Dermatological Treatment, 2011, 22, 366-371.	2.2	32
211	Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease. Dermatology, 2011, 222, 330-335.	2.1	11
212	The psoriatic patient profile for infliximab. European Review for Medical and Pharmacological Sciences, 2011, 15, 1445-51.	0.7	10
213	Usefulness of the Framingham Risk Score in Patients With Chronic Psoriasis. American Journal of Cardiology, 2010, 106, 1754-1757.	1.6	53
214	Psoriasis, the liver, and the gastrointestinal tract. Dermatologic Therapy, 2010, 23, 155-159.	1.7	35
215	The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis. Dermatology, 2010, 221, 6-14.	2.1	18
216	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. Journal of Rheumatology, 2010, 37, 448-452.	2.0	18

#	ARTICLE	IF	CITATIONS
217	C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1195-1202.	2.1	31
218	Erythema nodosum: etiological factors and relapses in a retrospective cohort study. <i>European Journal of Dermatology</i> , 2010, 20, 773-7.	0.6	15
219	Metabolic Syndrome in Psoriasis. , 2010, , 95-98.		1
220	Metabolic comorbidities and psoriasis. <i>Acta Dermatovenerologica Croatica</i> , 2010, 18, 297-304.	0.1	32
221	Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness. <i>Dermatology</i> , 2009, 218, 110-113.	2.1	109
222	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. <i>Dermatology</i> , 2009, 219, 158-161.	2.1	6
223	Psoriasis and Atherothrombotic Diseases: Disease-Specific and Non-Disease-Specific Risk Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 313-324.	2.7	86
224	A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 304-308.	1.3	9
225	Microcirculatory modifications of psoriatic lesions during topical therapy. <i>Skin Research and Technology</i> , 2009, 15, 135-138.	1.6	39
226	Psoriasis and systemic inflammation: underdiagnosed enthesopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 3-8.	2.4	57
227	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	2.4	683
228	Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 14-21.	0.4	26
229	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. <i>Journal of Hepatology</i> , 2009, 51, 758-764.	3.7	217
230	Efficacy of a Single Educative Intervention in Patients with Chronic Plaque Psoriasis. <i>Dermatology</i> , 2009, 219, 316-321.	2.1	30
231	Perception of Disease and Doctor-Patient Relationship Experienced by Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 325-330.	6.7	39
232	The Handbook of Differential Diagnosis for the Dermatologist. <i>European Journal of Dermatology</i> , 2009, 19, 195-195.	0.6	0
233	Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. <i>Dermatologic Therapy</i> , 2008, 21, S31-S38.	1.7	29
234	Anti-tumour necrosis factor therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 341-344.	2.4	166

#	ARTICLE	IF	CITATIONS
235	Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. <i>British Journal of Dermatology</i> , 2008, 158, 1345-1349.	1.5	135
236	Targeting tumor necrosis factor $\hat{\pm}$ in psoriasis and psoriatic arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1085-1096.	3.4	58
237	Psoriasis and Metabolic Comorbidities: The Importance of Well-Designed Prospective Studies. <i>Dermatology</i> , 2008, 217, 222-224.	2.1	8
238	Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 26-30.	0.9	249
239	Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 1242-7.	4.7	214
240	Folic acid in general medicine and dermatology. <i>Journal of Dermatological Treatment</i> , 2007, 18, 138-146.	2.2	59
241	Psoriasis and Risk of Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 361.	7.4	7
242	Impairment of Sexual Life in Patients with Psoriasis. <i>Dermatology</i> , 2007, 214, 144-150.	2.1	104
243	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. <i>British Journal of Dermatology</i> , 2007, 157, 68-73.	1.5	543
244	Combination of efalizumab and acitretin in chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070619172136002-???	2.4	4
245	Biologic therapies in psoriasis: A new therapeutic approach. <i>Autoimmunity Reviews</i> , 2007, 6, 515-519.	5.8	83
246	Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 1165-1169.	1.5	120
247	Insufficient Knowledge Among Psoriasis Patients Can Represent a Barrier to Participation in Decision-making. <i>Acta Dermato-Venereologica</i> , 2006, 86, 528-534.	1.3	40
248	Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: A case study. <i>Journal of Dermatological Treatment</i> , 2006, 17, 172-175.	2.2	12
249	Autoimmune progesterone dermatitis. <i>Gynecological Endocrinology</i> , 2006, 22, 54-56.	1.7	30
250	Pimecrolimus in dermatology: atopic dermatitis and beyond. <i>International Journal of Clinical Practice</i> , 2005, 59, 969-974.	1.7	47
251	Severe Impairment of Quality of Life in Hailey-Hailey Disease. <i>Acta Dermato-Venereologica</i> , 2005, 85, 132-135.	1.3	31
252	Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. <i>European Journal of Dermatology</i> , 2005, 15, 279-83.	0.6	73

#	ARTICLE	IF	CITATIONS
253	Targeting Tumor Necrosis Factor- $\alpha$ in the Therapy of Psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 175-183.	3.1	43
254	Prevalence of symptoms experienced by patients with different clinical types of psoriasis. <i>British Journal of Dermatology</i> , 2004, 151, 594-599.	1.5	174
255	An itchy vesiculobullous eruption in a patient with chronic lymphocytic leukaemia. <i>International Journal of Clinical Practice</i> , 2004, 58, 1177-1179.	1.7	15
256	H1 histamine receptor mediates inflammatory responses in human keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1176-1182.	2.9	107
257	Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 126-131.	1.2	71
258	Immunoregulation of Allergic Contact Dermatitis. <i>Journal of Dermatology</i> , 2004, 31, 264-270.	1.2	55
259	Disseminated lupus vulgaris. <i>European Journal of Dermatology</i> , 2003, 13, 500-2.	0.6	3
260	Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. <i>Global &amp; Regional Health Technology Assessment</i> , 0, 8, 120-130.	0.1	1